Patent application number | Description | Published |
20100152441 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS - The present invention relates to compounds that demonstrate antibacterial activity, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans. In particular this invention relates to compounds useful for the treatment of bacterial infections in warm-blooded animals such as humans, more particularly to the use of these compounds in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans. | 06-17-2010 |
20110092495 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS - The present invention relates to compounds that demonstrate antibacterial activity, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans. In particular this invention relates to compounds useful for the treatment of bacterial infections in warm-blooded animals such as humans, more particularly to the use of these compounds in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans. | 04-21-2011 |
20120108577 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS - The present invention relates to compounds that demonstrate antibacterial activity, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans. In particular this invention relates to compounds useful for the treatment of bacterial infections in warm-blooded animals such as humans, more particularly to the use of these compounds in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans. | 05-03-2012 |
Patent application number | Description | Published |
20140254773 | EMERGENCY CALLING TECHNIQUES - Embodiments of the invention provide systems and methods for handling emergency calls. According to one embodiment, handling an emergency call can comprise receiving an emergency call from a calling number, determining whether the calling number has been ported from an original geographic location to a new geographic location, determining a spatial location for the calling number based at least in part on whether the calling number has been ported, identifying a public safety system for handling the emergency call based on the determined spatial location for the calling number, and routing the emergency call to the identified public safety system. Identifying the public safety system for handling the emergency call can comprise using a point-in-polygon check of the determined spatial location for the calling number against known spatial boundaries for a plurality of public safety systems. | 09-11-2014 |
20140334346 | DYNAMIC 911 LOCATION REGISTRATION FOR MOBILE VoIP DEVICE - Embodiments of the present invention are directed to methods and systems for handling emergency calls from a mobile VoIP device. According to one embodiment, handling an emergency call from a Voice-over Internet Protocol (VoIP) device can comprise registering a physical address associated with the mobile VoIP device, periodically determining a current location of the mobile VoIP device, dynamically updating a current address associated with the mobile VoIP device based on the determined current location of the mobile VoIP device, and initiating an emergency call from the mobile VoIP device, the emergency call selectively using either the registered physical address or the dynamically updated current address. | 11-13-2014 |
20150237469 | DYNAMIC 911 LOCATION REGISTRATION FOR MOBILE VoIP DEVICE - Embodiments of the present invention are directed to methods and systems for handling emergency calls from a mobile VoIP device. According to one embodiment, handling an emergency call from a Voice-over Internet Protocol (VoIP) device can comprise registering a physical address associated with the mobile VoIP device, periodically determining a current location of the mobile VoIP device, dynamically updating a current address associated with the mobile VoIP device based on the determined current location of the mobile VoIP device, and initiating an emergency call from the mobile VoIP device, the emergency call selectively using either the registered physical address or the dynamically updated current address. | 08-20-2015 |
Patent application number | Description | Published |
20100003258 | FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS - Monoclonal antibodies that bind and inhibit activation of fibroblast growth factor receptor 3 (FGFR3) are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of FGFR3. | 01-07-2010 |
20100173361 | Hepatocyte Growth Factor (HGF) Binding Proteins - The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors. | 07-08-2010 |
20110229462 | Hepatocyte Growth Factor (HGF) Binding Proteins - The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors. | 09-22-2011 |
20110236377 | Hepatocyte Growth Factor (HGF) Binding Proteins - The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors. | 09-29-2011 |
20110256154 | ANTI-ERBB3 ANTIBODIES - Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3. | 10-20-2011 |
20120027773 | ANTI-RON ANTIBODIES - Monoclonal antibodies that bind and inhibit activation of human RON (Recepteur d' Origine Nantais) are disclosed. The antibodies can be used to treat certain forms of cancer that are associated with activation of RON. | 02-02-2012 |
20130203963 | HEPATOCYTE GROWTH FACTOR (HGF) BINDING PROTEINS - The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors. | 08-08-2013 |
20130203970 | HEPATOCYTE GROWTH FACTOR (HGF) BINDING PROTEINS - The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors. | 08-08-2013 |
20130330772 | ANTI-ERBB3 ANTIBODIES - Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3. | 12-12-2013 |
20140066603 | ANTI-RON ANTIBODIES - Monoclonal antibodies that bind and inhibit activation of human RON (Recepteur d'Origine Nantais) are disclosed. The antibodies can be used to treat certain forms of cancer that are associated with activation of RON. | 03-06-2014 |
20140178934 | HEPATOCYTE GROWTH FACTOR (HGF) BINDING PROTEINS - The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors. | 06-26-2014 |
20140178935 | HEPATOCYTE GROWTH FACTOR (HGF) BINDING PROTEINS - The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors. | 06-26-2014 |
Patent application number | Description | Published |
20090063361 | Risk and Reward Assessment Mechanism - A data driven and forward looking risk and reward appetite methodology for consumer and small business is described. The methodology includes customer segmentation to create pools of homogeneous assets in terms of revenue and loss characteristics, forward looking simulation to forecast expected values and volatilities of revenue and loss, and risk and reward optimization of the portfolio. One methodology used for modeling revenue and loss is a generalized additive effect decomposition model to fit historical data. Based on the model, a segmentation procedure is performed, which allows for creation of groups of customers with similar revenue and loss characteristics. An estimation procedure for the model is developed and a simulation strategy to forecast and simulate revenue and loss volatility is developed. Efficient frontier curves of risk (e.g., return volatility) and reward (e.g., expected return) are created for the current portfolio under various economic scenarios. | 03-05-2009 |
20100293107 | Risk and Reward Assessment Mechanism - A data driven and forward looking risk and reward appetite methodology for consumer and small business is described. The methodology includes customer segmentation to create pools of homogeneous assets in terms of revenue and loss characteristics, forward looking simulation to forecast expected values and volatilities of revenue and loss, and risk and reward optimization of the portfolio. One methodology used for modeling revenue and loss is a generalized additive effect decomposition model to fit historical data. Based on the model, a segmentation procedure is performed, which allows for creation of groups of customers with similar revenue and loss characteristics. An estimation procedure for the model is developed and a simulation strategy to forecast and simulate revenue and loss volatility is developed. Efficient frontier curves of risk (e.g., return volatility) and reward (e.g., expected return) are created for the current portfolio under various economic scenarios. | 11-18-2010 |
20130073481 | Risk and Reward Assessment Mechanism - A data driven and forward looking risk and reward appetite methodology for consumer and small business is described. The methodology includes account level historical data collection for customers associated with accounts as part of a portfolio. The account level historical data is segmented into groups of customers with similar revenues and loss characteristics. Segmented data is decomposed into seasoning, vintage, and cycle effects. Statistical clusters are formed based upon the data and effects. A simulation is applied to the statistical clusters and prediction data is generated. A simulation strategy to forecast and simulate revenue and loss volatility is developed. Efficient frontier curves of risk (e.g., return volatility) and reward (e.g., expected return) are created for the current portfolio under various economic scenarios. | 03-21-2013 |